Higher Circulating Levels of Chemokine CCL22 Associated with Breast Cancer

Strategic Insights -

A recent study published in Tumor Biology has found a significant association between higher circulating levels of chemokine CCL22 and breast cancer in patients. The study, conducted by researchers at Shiraz University of Medical Sciences, aimed to evaluate the serum CCL22 levels and a single nucleotide polymorphism (SNP) in the chemokine gene in patients with breast cancer.

The researchers collected blood samples from 100 women with breast cancer before receiving chemotherapy, radiotherapy, or immunotherapy and 100 age-matched healthy women as a control group. The serum CCL22 levels were measured using ELISA, and the DNA extracted and the SNP rs223818 determined by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique. The results showed that the mean serum CCL22 levels in patients with breast cancer (2398.5 ± 123 Pg/mL) were significantly higher compared to the healthy control group (974.2 ± 39.9 Pg/mL; P.

The study also found that the SNP rs223818 may play a role in the susceptibility to breast cancer. According to the research, "Accordingly, SNP rs223818 may play a role in the susceptibility to breast cancer." This suggests that genetic factors may contribute to the development of breast cancer.

Key Takeaways:

  • The study found a significant association between higher circulating levels of chemokine CCL22 and breast cancer in patients.
  • The mean serum CCL22 levels in patients with breast cancer (2398.5 ± 123 Pg/mL) were significantly higher compared to the healthy control group (974.2 ± 39.9 Pg/mL; P.
  • The SNP rs223818 may play a role in the susceptibility to breast cancer.
  • The study suggests that genetic factors may contribute to the development of breast cancer, particularly the rs223818 SNP.
  • The chemokine CCL22 may act as a chemoattractant for the intratumoral Treg migration in breast cancer patients.
  • The study highlights the potential role of chemokine CCL22 in the progression and metastasis of breast cancer.

Statistics:

  • The study included 100 women with breast cancer and 100 age-matched healthy women as a control group.
  • The serum CCL22 levels were measured using ELISA, and the mean levels in patients with breast cancer (2398.5 ± 123 Pg/mL) were significantly higher compared to the healthy control group (974.2 ± 39.9 Pg/mL; P.
  • The study found a significant association between higher circulating levels of chemokine CCL22 and breast cancer in patients (P.
  • The SNP rs223818 was determined by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique in 100 patients with breast cancer.

Sources:

  • Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism. Tumor Biology, 2015;36(2):1163-1171.
  • Shiraz University of Medical Sciences.
  • Springer (www.springer.com).
  • Tumor Biology (www.springerlink.com/content/1010-4283/).